iX Biopharma (SGX:42C) Total Equity: S$17.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:42C iX Biopharma Ltd SGX:42C
36 GF Score
Price S$0.55
GF Value S$0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is iX Biopharma Total Equity?

iX Biopharma SGX:42C +0.92% 36 Total Equity is S$17.00 Mil as of Mar. 2026. GuruFocus rates SGX:42C with a GF Score™ of 36/100 and a GF Value™ of S$0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

iX Biopharma's total equity for the quarter that ended in Mar. 2026 was S$17.00 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

iX Biopharma Total Equity Historical Data

* Premium members only.

The historical data trend for iX Biopharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iX Biopharma Total Equity Chart

iX Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.71 19.74 15.85 4.34 0.37

iX Biopharma Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.51 0.00 0.37 4.13 17.00
SGX:42C
36GF Score
iX Biopharma Ltd SGX:42C
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iX Biopharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

iX Biopharma's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=11.284-10.919
=0.37

iX Biopharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=27.361-10.36
=17.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of S$17.00 Mil mean?
iX Biopharma (SGX:42C) has a Total Equity of S$17.00 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for iX Biopharma and its competitors.
Is iX Biopharma's Total Equity too high?
iX Biopharma's current Total Equity is S$17.00 Mil. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Total Equity compare to ZTS and UTHR?
iX Biopharma's Total Equity of S$17.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for iX Biopharma and its competitors. iX Biopharma's current Total Equity is S$17.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1733.3% above its estimated fair value. The current Total Equity is S$17.00 Mil. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Total Equity is S$17.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iX Biopharma (SGX:42C) Overvalued in 2026?

Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued. The current stock price of S$0.55 is trading 1733.3% above its estimated GF Value™ of S$0.03. GuruFocus considers iX Biopharma to be Significantly Overvalued.

Key valuation signals for SGX:42C:

  • Total Equity: S$17.00 Mil
  • GF Value™: S$0.03 vs. price of S$0.55 (1733.3% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iX Biopharma Business Description

Address 1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score

Get the complete analysis for SGX:42C

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.55
Price
S$0.03
GF Value